Nimesulide and Celecoxib Inhibits Multiple Oncogenic Pathways in Gastric Cancer Cells

Jayaprakash Periasamy1, Muthulakshmi Muthuswami1, Vignesh Ramesh1, Thangaselvam Muthusamy1, Amrita Jain1, Chandrabose Karthikeyan2, Piyush Trivedi2, Rayala Suresh Kumar3, Paramasamy Gunasekarani, Sun Young Rha4, Partick Tan5 and Ganesan Kumaresan1

1Cancer Genetics Laboratory, Department of Genetics, Centre for Excellence in Genomic Sciences, School of Biological Sciences, Madurai Kamaraj University, Madurai, India
2School of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Viswavidyalaya, University of Technology of Madhya Pradesh, Gandhi Nagar, Bhopal, India
3Department of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai, India
4Department of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, South Korea
5Duke-NUS Graduate Medical School Singapore, 8 College Road, Singapore

Abstract

Despite being the leading cause of cancer death, targeted therapy for gastric cancer is yet to be established. Wnt/β-catenin signaling is highly deregulated in cancers of gastrointestinal origin including gastric cancers. Stabilization and deregulation of β-catenin occurs at multiple levels and so is being needed to identify a spectrum of Wnt inhibitors to combat deregulated Wnt signaling at the level of various targets and also in different combinations. We developed a luciferase reporter based gastric cancer cellular assay system for Wnt pathway modulator screening and identified nimesulide, a known COX-2 inhibitor as an inhibitor of Wnt/β-catenin signaling pathway. Comprehensive signaling pathway profiling revealed that nimesulide could inhibit STAT3, IRF1 and RXR signaling apart from inhibiting Wnt/β-catenin-Myc-E2F signaling cascade. Nimesulide elicits a strong anti-proliferative effect by promoting cell cycle arrest in multiple gastric cancer cell lines. Inhibition of Wnt and STAT3 signaling are found to be COX-2 independent, while the inhibition of RXR and IRF1 pathways are due to the COX-2 inhibiting feature of nimesulide. While nimesulide is capable of activating Notch signaling in gastric cancer cells, celecoxib inhibits Wnt, Myc, E2F, RXR, STAT3, MAPK and Notch signaling pathways in gastric cancer cells. Signaling pathway focused analysis of gastric cancer transcriptome revealed that Wnt, STAT3, IRF1 and RXR signaling pathways are highly deregulated in majority of gastric tumors and indicates the potential of nimesulide and celecoxib class of drugs for targeted gastric cancer therapeutics. The differential inhibition of multiple signaling by nimesulide and celecoxib deserve further investigation.

Keywords: Celecoxib; COX2; Gastric cancer therapeutics; Nimesulide; NSAID; Wnt/β-catenin signaling

Abbreviations: COX-2: Cyclooxygenase-2; ERK/MAPK: Extracellular Signal-Regulated Kinase Regulated Mitogen-Activated Protein Kinase Signaling; GEO: Gene Expression Omnibus; MSigDB: Molecular Signatures Database; NSAID: Non-Steroidal Anti Inflammatory Drug; PGE2: Prostaglandin E2; RT-PCR: Reverse Transcription Polymerase Chain Reaction; RXR: Retinoid X Receptor; STAT3: Signal Transducer and Activator of Transcription 3

Introduction

Stomach cancer is the second leading cause of global cancer mortality and estimated as fourth common cancer worldwide [1,2]. Deregulation in the growth signaling pathways due to genetic alterations often persuades normal cells to undergo transformation and cancer development [3]. Among the deregulated signaling, Wnt/β-catenin signaling plays a predominant role in gastric tumorigenesis and the recent pathway focused investigation of gastric cancer transcriptome has shown the deregulation of Wnt/β-catenin signaling in 46% of patients [4]. Several members of Wnt/β-catenin pathway like APC, CDH1, CTNNB1 and AXIN2 [5-7] are often mutated and being the primary causative factors which makes the β-catenin nonresponsive to APC/AXIN2/GSK-3β destruction complex. This results in cytosolic stabilization and nuclear accumulation of β-catenin and drives transcriptional activation of Wnt target genes [8]. Apart from its own activation, increasing evidences show that Wnt signaling involves in molecular conversation with other oncogenic counterparts such as MAPK, PI3K/AKT, STAT3 and Hedgehog [9-12] and potentiates cancer growth. Due to its key role in tumorigenesis, Wnt/β-catenin signaling is recognized as an attractive target for anticancer drug development [13]. However, none of the identified Wnt pathway specific inhibitors have reached clinical trials and hence Wnt pathway based targeted therapy is lagging behind [14]. Many of the earlier Wnt/β-catenin signaling modulator screening methods involved non-cancerous cells [15] where there is a possibility that identified inhibitors acting upstream of β-catenin may not be effective in targeting Wnt signaling in cancer cells with defect(s) in pathway component genes like β-catenin. Therefore, the discovery of inhibitors which act around the stabilized β-catenin through the disruption of transcriptional response would facilitate prominent targeted therapeutic effect in wide range of tumors and such specific screening systems are largely lacking.

Some of the clinically practiced drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) [13], analgesics and antibacterial agents [16], have been identified as inhibitors of Wnt signaling. NSAIDs are preferentially cyclooxygenase (1/2) inhibitors, work through suppression of inflammation mediated by prostaglandin.
NSAIDs with distinct structures like aspirin, indomethacin, ibuprofen, sulindac exhibit considerable interest as anticancer agents. Indeed, many epidemiological studies have highlighted the chemopreventive effect of aspirin and other NSAIDs upon regular use by reducing the incidence and severity of human cancers [17,18]. Aspirin and celecoxib have become potent inhibitors of constitutive Wnt signaling and able to reduce the polyt formation, tumorigenesis and elicits anti tumor response in many cancers including gastric cancer [17,19-22]. Over-expression of COX-2 is frequently observed in gastric cancer with ~50% frequency and is also associated with lymphatic metastasis and poor prognosis [23,24]. Indeed, COX-2 gene expression in gastric cancer cells is also regulated by Wnt/β-catenin signaling [25]. Therefore identification of inhibitors which promotes blockade of Wnt and COX-2 activity in gastric cancer cells would pave way for developing targeted therapeutics for clinical management of gastric cancer. In order to identify potential inhibitors for deregulated and constitutive Wnt transcriptional response, we established a cell based assay system with stably maintained TCF responsive genetic reporter system in a gastric cancer cell line with constitutive Wnt signaling owing to mutant β-catenin. Nimesulide, one of the COX-2 inhibitors has been identified as Wnt inhibitor through screening a panel of drugs and further investigated its Wnt dependent/independent and COX-2 dependent/independent effects on multiple oncogenic signaling pathways in gastric cancer cell lines in an unbiased manner. This investigation reveals the possible therapeutic repositioning candidacy of nimesulide derivatives and celecoxib for the development of gastric cancer therapeutics.

Materials and Methods

Cell lines and culture

The human gastric cancer cell line AGS was obtained from National Centre for Cell Science (NCCS), Pune, India. Kato-III was obtained from ATCC, USA, and MKN45 cells were from Japan Health Science Research Resource Bank. Gastric cancer cell lines YCC3 and YCC16 cell lines were kind gift from Dr. Sun Young Rha, Yonsei Cancer Centre, Korea. AGS cell line was cultured in Dulbecco's Modified Eagle Medium / Nutrient mixture F-12 Ham (HiMedia, India) supplemented with 10% Fetal bovine serum (Sigma), Kato-III was cultured in RPMI-1640 (HiMedia, India) supplemented with 20% FBS, MKN45 cells in RPMI-1640 with 10% FBS and YCC3, YCC16 cell lines were propagated in MEM (HiMedia, India) with 10% FBS under standard cell culture conditions. All the cell culture flask, multi-well plates and dishes were from Corning. The cell lines were authenticated by Affymetrix Centre, Korea. AGS cells and 48 hours later, cells were selected with 200 μg/ml of hygromycin B and the stable pools were further expanded.

Cytotoxicity and cell proliferation assay

Dose dependent cytotoxicity and time-course cell proliferation assays were performed in 96 well cell culture plates. After the treatment time points, MTT reagent was added to the wells (Bio Basic Inc) and incubated for 4 hours. Subsequently, formazan was dissolved in DMSO and measured calorimetrically at 570 nm. Optical density in comparison to the control cells were measured and plotted as cell viability.

Pathway profiling in gastric cancer cell lines by Cignal 45 pathway reporter array

Gastric cancer cell lines were seeded in 96 well cell culture plates and transfected with Cignal 45 pathway reporter array panel of plasmids (SA Biosciences). The plasmids used for 45 signaling pathways are: pSTAT3-FLUC, pIRF1-FLUC, pHXR-FLUC, pWnt-FLUC, pE2F1-DP1-FLUC, pMyC/Max-FLUC, pATF4/32-FLUC, pAndrogen Receptor-FLUC, pNrf2 & Nrf1-FLUC, pATF6-FLUC, pC/EBP-FLUC, pCREB-FLUC, pE2F/DP1-FLUC, pP35-FLUC, pERG1-FLUC, pCBF/ NF-Y/Y1-FLUC, pEstarogen Receptor (ER)-FLUC, pGATA-FLUC, pGlucocorticoid Receptor (GR)-FLUC, pHSF-FLUC, pHNF4-FLUC, pMTF1-FLUC, pGLI-FLUC, pHypoxia-inducible factor (HIF)-1-FLUC; pSTAT1/STAT2-FLUC, pSTAT1/STAT1-FLUC, pKL4FLUC, pLXR-FLUC, pERK-1/2/3/4-FLUC, pP38-FLUC, pNanog-FLUC, pNkx-1-FLUC, pP2AB-FLUC, pP2PB-JK-FLUC, pPcx-FLUC, pPax6-FLUC, pPFOX-FLUC, pPNAFLUC, pPPAR-FLUC, pProgesterone Receptor-FLUC, pRetinoic Acid Receptor (RAR)-FLUC, pS02X-FLUC, pSPI-FLUC, pSMAD2/3-4-FLUC, pVitamin-D Receptor-FLUC, pAh-RFLUC, pCMV-FLUC and pCMV-RENilla. In each well, a pathway specific reporter plasmid was transfected along with renilla luciferase internal control plasmid (pCMV-RLUC) at 100:1 ratio. 24 Hrs after transfection, cells were treated with drugs and incubated for 24 hours and then dual luciferase assays were performed. For luciferase reporter assays, the cells were lysed with 1X passive lysis buffer (Promega) and the luciferase activity assay was performed by dual-luciferase reporter assay protocol described [26] using luciferin (Life Science Technologies) and Coelenterazin (Gold Biotechnology). Firefly and Renilla luciferase activities were measured in Spectramax L microplate luminometer (Molecular Devices).

Antibodies and Western blotting

Gastric cancer cells treated with nimesulide were subjected to protein extraction and western blotting. Specific antibodies were used for the detection of cellular levels of β-catenin (219353, CalBiochem), CyclinD1 (SC-8396, Santa Cruz Biotechnology), cMyc (SC-40, Santa Cruz Biotechnology), APC (SC-9998, Santa Cruz Biotechnology), GSK3β (SC-9166), and phospho-GSK3β (SC-11757, Santa Cruz Biotechnology). Celecoxib treated cell lysates were probed with p42/p44 MAPK antibody (#9107, Cell signaling) and phospho-p42/p44 MAPK antibody (#9106, Cell signaling) for the analysis of MAPK regulation. Anti-β-actin (#A1978, Sigma) and Anti-Vinculin (sc-25336, Santa Cruz Biotechnology) antibodies were used to detect internal control proteins β-actin and vinculin. Bolts were developed using Western Lightning Plus-ECL, chemiluminescence substrate (PerkinElmer).
PGE2 treatment and RT-PCR

Gastric cancer cell lines were seeded in 24 well plates and maintained in serum deprived conditions for 24 hours. Subsequently, the cells were transfected with signaling pathway specific firefly reporter plasmids (pSTAT3-FLUC, pRIF1-FLUC, pRXR-FLUC, pWnt-FLUC, pCREB-FLUC) along with CMV-FLUC renilla luciferase reporter plasmid at 100:1 ratio. 24 Hrs later, the cells were treated with varying concentrations of PGE2 and assayed by dual luciferase assay upon 12 hours of incubation.

AGS cells seeded in 6 well culture plate were treated with increasing concentration of nimesulide and celecoxib and incubated for 48 hours. Subsequently, total RNA was extracted using Trizol (Invitrogen) and cDNA was synthesized from the isolated RNA using Reverse Transcripase (Invitrogen) as per the standard protocol. cDNA was used for further semi-quantitative RT-PCR experiments to analyze the relative gene expression using gene specific primers.

Cell cycle analysis by flow-cytometry

For cell cycle analysis, cell lines were treated with drugs and stained with Propidium Iodide (BD Biosciences) and analyzed in the flow-cytometry. The staining procedures for cell cycle analysis were followed according to manufacturer’s instructions. FlowJo software was used for data analysis.

Signature based pathway activation in primary gastric tumor microarray data

Gene expression profile data for independent gastric cancer cohorts were obtained from GEO database. Pathway specific gene signatures used in this study were obtained from MSigDB database (http://www.broad.mit.edu/gsea/msigdb/genesets) and from research articles. Details of the signatures and their sources are available in supplementary table S2. Each signature is represented by a gene set and termed as query signature (QS). Depending on the signature, a QS may consist of up and / or down-regulated genes, i.e. genes up or down regulated upon the activation of the specific signaling pathway. Scoring of pathway activation in gastric tumors was performed from the gene expression profile of the tumors, based on gene signature enrichment analysis. Gene signature based pathway activation prediction method described previously was followed [27].

Statistical Analysis

The experiments carried out in the study were triplicates and data represented as mean ± SEM. Statistical comparison of values were made using two-tailed Student’s t test, and statistical significance was considered to be present when P < 0.05.

Results

Nimesulide inhibits Wnt/β-catenin signaling and promotes growth arrest in gastric cancer cells

Identification of potential Wnt inhibitors is the prime step in the development of therapeutics against Wnt/β-catenin activated gastric cancers. For the screening and identification of Wnt/β-catenin inhibitors, AGS-pWnt-luc reporter stable cells were generated by transfecting pWnt-luc, luciferase reporter plasmid in AGS cell line (Wnt/β-catenin hyperactive cells) and selecting stable cells with hygromycin-B. AGS-pWnt-luc reporter stable cells were evaluated by modulating Wnt/β-catenin signaling by i) GSK3β inhibitor (Wnt activator) Lithium chloride, ii) Wnt inhibitor Diclofenac and iii) CTNNB1 knockdown, which all significantly altered the Wnt reporter activity (Figure 1A).

Subsequently, Wnt inhibitor screening was performed with a small compound library using AGS-pWnt-luc reporter cells. Luciferase reporter activity was normalized with cell viability assay and compounds that modulated the Wnt reporter activity above 2 folds were further screened (Figure 1B and Supplementary Table S1). One of the compounds, nimesulide was consistent in inhibiting TCF reporter activity in multiple independent assays and also evoked dose dependent response. Inhibition of TCF reporter activity (P=0.0005) was further confirmed by transient dual reporter assay by normalizing the activity of firefly luciferase with renilla luciferase (Figure 1C and Supplementary Figure S1A). Thus Wnt/β-catenin pathway modulator screening reporter system is established in gastric cancer cell line, and a novel Wnt inhibition potential of nimesulide has been identified from the initial screening. To functionally evaluate the effect of nimesulide on cell viability and proliferation in gastric cancer cells, MTT assay was performed and shows inhibition in cell viability at higher concentrations in AGS cells (Figure 1D). Further, nimesulide elicits strong growth inhibition in multiple gastric cancer cell lines at the identified effective dose of Wnt inhibition (100 μM) (Figure 1E).

Nimesulide stabilizes APC/GSK3β destruction complex and promotes degradation of β-catenin

Cell cycle phase analysis upon nimesulide treatment (100 μM) shows significant reduction in S-phase population (P<0.02) and elevation of G1-populations which is an indication of G1-S phase arrest (Figure 2A) and this is associated with down-regulation of E2F1 reporter activity (P = 0.04) and Myc reporter activity (P=0.05) (Figures 2B and 2C). Thus nimesulide promotes growth arrest in gastric cancer cells through the inhibition of E2F1 dependent cell cycle progression. To investigate the mechanism of inhibition of Wnt signaling and G1-S phase arrest by nimesulide, panel of gastric cancer cells with high β-catenin expression such as AGS, Kato-III, and MKN45 were investigated for the effect of nimesulide treatment in cellular β-catenin levels and target protein c-Myc and CyclinD1 expression. AGS, Kato-III and MKN45 cells were treated with increasing concentrations of nimesulide for 24 hours and the expression of proteins were analyzed by western blotting. Interestingly, β-catenin level is reduced at the increasing concentrations of nimesulide in all the cell lines along with the down-regulation CyclinD1. c-Myc was found down-regulated in AGS and MKN45 cells (Figure 2D and Supplementary Figure S1B). CyclinD1 is a positive regulator of E2F1 mediated progression of G1-S transition [28] and thus the β-catenin dependent down-regulation of CyclinD1 by nimesulide treatment is the underlying mechanism of growth arrest in gastric cancer cells. To address the mode of β-catenin protein reduction by nimesulide, the activation of APC/GSK3β destruction complex was suspected and investigated. AGS, Kato-III and MKN45 cells were treated with nimesulide and the expression of APC, GSK3-β and phospho-GSK3-β (ser9) were analyzed. Nimesulide treatment increased APC protein level and promotes activation of APC/GSK3β destruction complex as suspected and investigated. AGS, Kato-III and MKN45 cells were treated with nimesulide and the expression of APC, GSK3-β and phospho-GSK3-β (ser9) were analyzed. Nimesulide treatment increased APC protein level and promotes activation of GSK3β by reducing inactivating phosphorylation at serine-9 residue in multiple Wnt activated gastric cancer cell lines (Figure 2E and Supplementary Figure S1C). These results show that nimesulide inhibits Wnt/β-catenin signaling through APC/GSK3β mediated destruction of β-catenin, which also results in the inhibition of Myc/E2F1 mediated transcription and G1-S transition.

Nimesulide inhibits Wnt/β-catenin signaling through COX-2 independent mechanism

It is known that COX-2 regulates Wnt/β-catenin signaling by positive feedback loop in cancer cells through prostaglandin E2 (PGE2) [29], and hence we initially hypothesized COX-2 dependency...
in Wnt/β-catenin signaling inhibition by nimesulide. Presumably, inhibition of COX-2 by nimesulide could lead to the blockade of PGE2 (the product of COX-2) which in turn might inhibit Wnt activation loop. By comparing TCF reporter activity and PTGS2 gene expression across a panel of gastric cancer cell lines, Kato-III was identified as a Wnt activated but COX-2 negative cell line and AGS cell line as Wnt activated and COX-2 expressing cell line (Figure 3A). Initially, the existence of COX-2 mediated Wnt activation loop was evaluated by exogenous PGE2 treatment followed TCF and CREB reporter assay in AGS cells. PGE2 treatment results in activation of TCF reporter activity in dose dependent manner and shows COX-2 responsive Wnt signaling (Figure 3B). CREB reporter was used as positive control as CREB can be activated by PGE2 [30]. Subsequently, we asked whether nimesulide inhibits Wnt signaling even in the presence of PGE2 to look for the possibility of COX-2 independency. In AGS cells, upon treating nimesulide at increasing concentrations along with constant level of PGE2 (32 μM), a significant down-regulation of TCF activity irrespective of PGE2 treatment was observed (Figure 3C). Further, in Kato-III cells (COX-2 non expressive), TCF activity was nonresponsive to PGE2 (Figure 3D). On the other hand, nimesulide inhibits Wnt signaling by reducing β-catenin level (Figure 2D) and the concomitant down-regulation of TCF reporter activity in Kato-III cells (Figure 3E). All these suggest that inhibition of Wnt signaling by nimesulide is independent of its COX-2 inhibiting capability in gastric cancer cells.

**Nimesulide modulates cellular STAT3, IRF1 and RXR response in gastric cancer cells**

To investigate the other possible pathway modulatory effects in global scale, we performed a multi-signaling pathway profiling upon nimesulide treatment (100 μM) in AGS cells (Figure 4A). This comprehensive pathway profiling comprises luciferase based reporter assays for a panel of 45 distinct cellular genomic signaling responses. Upon nimesulide treatment, the pathways which consistently showed more than 2 folds up/down-regulations were taken for further analysis. Interferon Regulatory factor-1 (IRF-1), Retinoic acid X Receptor (RXR) and Signal Transducer and Activator of Transcription 3 (STAT3) responsive reporter activities were consistently and significantly down regulated (P<0.01 (RXR), 0.004 (IRF1), 0.05 (STAT3)) by nimesulide in AGS cells. IRF1 is interferon stimulated transcription factor and RXR is retinoic acid regulated nuclear receptor acts as transcriptional co-activator/repressor which controls cell growth and survival [31,32]. STAT3 signaling known to promote aggressiveness in gastric cancer [33] is also modulated by nimesulide. Furthermore, nimesulide consistently inhibited IRF1, RXR and STAT3 pathways along with Wnt signaling in three different gastric cancer cell lines AGS, YCC3 and MKN45 (Figures 4B-D). In AGS cells, nimesulide reduces the expression of known IRF1 regulated genes IFI27 and IFI44 along with RXR signaling target gene NEDD9 (Figure 4E). This is the first report showing modulation of IRF1 and RXR signaling by nimesulide which all results in the concomitant inhibition of gastric cancer cell proliferation.

**Nimesulide modulates STAT3/IRF1/RXR signals through COX-2 dependent and independent mechanisms**

The regulation of IRF1, STAT3 and RXR signaling in gastric cancer is poorly understood. To delineate the mode of IRF1, RXR and STAT3 pathway modulations, Wnt/β-catenin and COX-2 pathways were modulated independently and looked for the impact on IRF1, STAT3
and RXR transcriptional activity. Exogenous PGE2 addition to represent COX-2 pathway activation enhanced the activity of IRF1, STAT3 and RXR in a dose dependent manner (Figure 5A) and moreover these pathways are non responsive to PGE2 in Kato-III cells (Supplementary Figure S2B). This implies that IRF1, STAT3 and RXR pathways are also regulated by the positive regulatory loop of COX-2/PGE2 in gastric cancer which is not identified before. While nimesulide inhibited IRF1 and RXR reporter activity ($P=0.05$), this inhibition was alleviated or abolished in the presence of PGE2 (Supplementary Figures S2C and S2D). Interestingly, STAT3 activity was inhibited even in the presence of PGE2 ($P=0.03$) (Figure 5B) and indicates COX2 independency in nimesulide mediated STAT3 inhibition. Inhibition of Wnt signaling in AGS by CTNNB1 knockdown significantly downregulated its downstream c-Myc and E2F1 transcriptional activities ($P=0.03$) and however, did not alter the IRF1, STAT3 and RXR activities (Figure 5C). All these suggest that nimesulide inhibits IRF1 and RXR through Wnt independent but by COX-2/PGE2 dependent regulatory mode. Conversely, STAT3 inhibition is mediated irrespective of COX-2 and Wnt/β- catenin signaling. Further, STAT3 itself did not show any influence on IRF1/RXR regulation (Supplementary Figure S2E).
Figure 3: Nimesulide inhibits Wnt/β-catenin signaling through COX-2 independent mechanism. A) Comparative Wnt signaling activity and PTGS2 (COX-2) expression across gastric cell lines as measured by reporter assay and RT-PCR respectively. B) Reporter assays indicating the positive regulation of Wnt/β-catenin and CREB to PGE2 treatment in AGS cells. C) Dose dependent inhibition of TCF activity by nimesulide in the presence of PGE2 in AGS cells. D) Wnt reporter activity in Kato-III cells upon the treatment of PGE2. E) Inhibition of TCF reporter activity by nimesulide in a dose dependent manner in Kato-III cells (COX-2 negative cell line) indicate COX-2 independency (*P = < 0.05, ***P = < 0.001).

Figure 4: Nimesulide alters the activity of STAT3, RXR and IRF1 signaling in gastric cancer cells. A) Comprehensive screening of nimesulide against 45 signaling pathways by corresponding transcription factor activity reporter assay in AGS cells. B-D) Nimesulide mediated inhibition of Wnt, IRF1, RXR and STAT3 pathways in AGS (B), MKN45 (C) and YCC3 (D) cell lines evaluated by reporter assay. E) RT-PCR showing nimesulide mediated downregulation of the expression of IF127, IFI44, and NEDD9, the target genes of IRF1 and RXR signaling pathways in AGS cells.
Nimesulide and celecoxib shares similar and distinct cellular signaling targets in eliciting anticancer effect

All the earlier experiments demonstrate nimesulide as a multi-target inhibitor, capable of promoting growth suppression in gastric cancer cells. Though nimesulide inhibits multiple signaling pathways, the activation of Notch is the undesirable event (Figure 3A). A therapeutic candidate having all the beneficial effects of nimesulide without Notch activating features would be more desirable. Upon screening a panel of NSAIDs against Notch signaling in gastric cancer cell lines (data not shown), celecoxib a counterpart of nimesulide was identified with these features. The effect of celecoxib on Wnt/β-catenin signaling was not tested in gastric cancer cell lines and hence AGS cells were treated with celecoxib and found to inhibit TCF reporter activity in a dose dependent manner (Figure 6A) and induces cell death (Supplementary Figure S3A). Celecoxib also inhibits the growth of multiple gastric cancer cell lines (Supplementary Figure S3B). Multi-pathway profiling for the identification of cellular signaling targets of celecoxib using 45 distinct reporter assays identified that pathways which are modulated by nimesulide like Wnt, STAT3, and RXR are also inhibited by Celecoxib at 10 μM concentration. Like nimesulide, RXR response was inhibited by celecoxib in a COX-2 dependent manner and STAT3 response through COX-2 independent manner (Supplementary Figures S3C and S3D). Celecoxib also was capable of inhibiting ERK/MAPK pathway reporter activity (Figure 6B). To evaluate the effect of celecoxib on ERK/MAPK response, AGS cells were treated with varying concentrations of celecoxib and the total p42/44 (Erk1/2) and Thr202/Tyr204 phosphorylated p42/44 (Erk1/2) proteins were analyzed. Celecoxib at 40 μM concentration markedly reduced the Thr202/Tyr204 phosphorylation of p42/44 (Erk1/2) (Figure 6C).

Inhibition of TCF reporter activity by nimesulide and celecoxib were found comparable with existing standard Wnt selective inhibitors PNU-74654 and IWR-1 in AGS cells (Figure 6D). Though nimesulide and celecoxib were known to exhibit chemo preventive effect in experimental animals and patients [19,34,35], the combinatorial effect of these drugs with chemotherapeutic drugs is unclear. To investigate the combinatorial effect with doxorubicin, AGS cells were treated with varying concentrations of doxorubicin along with sub-lethal dose of nimesulide (100 μM) or celecoxib (10 μM). Cell viability measured at 48 hours after treatment shows that both nimesulide and celecoxib act synergistic with doxorubicin by increasing the cell death while compared to doxorubicin treatment alone (Figure 6E).

**Signaling pathways modulated by nimesulide are highly deregulated in primary gastric tumors**

While nimesulide and celecoxib inhibits multiple oncogenic signaling pathways in gastric cancer cells, it is worth considering them as possible therapeutic candidates. However, the realistic involvement of the pathways modulated by these drugs in primary gastric tumors is not known and was investigated through integrated transcriptome-wide pathway specific gene-set enrichment analysis [4,27] in the mRNA expression profiles obtained from Gene Expression Omnibus (GEO), (GSE15459 and GSE22377) using pathway specific gene signatures obtained from MsigDB or respective publications (Supplementary Table S2). Pathway focused gene signature enrichment analysis in these two different gastric cancer datasets showed higher activation of Wnt (>35%) pathway followed by Myc, E2F1, IRF1, RXR and STAT3 activity upon CTNNB1 knockdown followed by reporter assay in AGS cell line. RT-PCR evaluation of CTNNB1 knockdown is shown inside.


siRNA biophysical screening [36-38], Wnt pathway based targeted therapy is still lagging behind. The underlying need for Wnt inhibitors is to inhibit the downstream Wnt responsive gene expression which otherwise potentiating cancer progression at various levels. Wnt/β-catenin signaling inhibitors acting at the level of β-catenin would work in any Wnt deregulated cancer cell and can elicit therapeutic effect in wide range of tumors. Therefore, we established a cell based Wnt/β-catenin inhibitor screening system capable of identifying Wnt inhibitors targeting Wnt signaling at the level of β-catenin or at β-catenin/TCF transcriptional activation. The gastric cancer cell line employed in this assay harbors a nuclear stabilized β-catenin which is found in significant proportion of primary gastric tumors [8]. While hunting for new inhibitors, the Wnt inhibitory properties of existing drugs also reported. Wnt pathway inhibitory effect of various non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, celecoxib, sulindac and indomethacin have been identified [20,21,39,40]. From our screen, the Wnt inhibiting effect of nimesulide was identified. The inhibition of TCF responsive activity by nimesulide and celecoxib are comparable with the specific Wnt inhibitors PNU-74654 & IWR-1. Nimesulide escalates significant cytotoxicity at higher concentrations of above 200 µM, but elicits potent antiproliferative and Wnt inhibitory effects in the range of 50-100 µM concentration and this indicates the reliable in vitro therapeutic index of nimesulide. It is known that NSAIDs take relatively higher concentrations (>50 µM) for their anticancer effects [41]. Nimesulide down regulates oncogenic c-Myc and E2F1 transcriptional activity which also leads to G1-S phase cell cycle arrest and growth inhibition. Inhibition of Wnt signaling by nimesulide is primarily not through COX-2 dependent mechanism. This indicates the existence of additional cellular targets of nimesulide in gastric cancer cells. A search for additional targets of nimesulide (apart from COX-2 and Wnt) at the level of cellular signaling by an unbiased pathway profiling approach has identified the modulation of IRF1, RXR and STAT3 signaling pathways by nimesulide. Among these, inhibition of IRF1 and RXR response by nimesulide is identified for the first time in this investigation. Inhibition of STAT3 and RXR by other NSAIDs like celecoxib, sulindac and etodolac were previously identified [42-45]. Sulindac (Exisulind) with Wnt, STAT3 and RXR inhibiting ability exhibits a promising inhibition of polyp formation in colorectal cancer clinical trials [46,47]. Similarly, celecoxib with Wnt and STAT3 inhibiting effects has shown encouraging survival outcome in clinical trials [48], and all these indicate that nimesulide or its derivatives could be potential candidates in targeted gastric cancer therapeutics. IRF-1 and RXR are the regulators of cell growth and proliferation in gastric and other cancers and also the oncogenic face of
interferon signaling and RXR are also been explained in human lymphocytic and promyelocytic leukemia [49,50]. In addition, gene signature enrichment analysis from our study shows activation of interferon signaling (IRF1) and RXR signaling in independent cohorts of primary gastric tumors and is the first documentation of deregulation in IRF1 and RXR signaling in gastric cancer. Moreover, nimesulide is found capable of inhibiting the expression of genes which are over-expressed in primary gastric tumors. Strikingly, the genes down-regulated by nimesulide are enriched with IRF and RXR transcription factor binding sites in addition to NFkB binding sites, which was not observed along with Wnt activation in a subset of intestinal type gastric tumors. Another COX-2 inhibitor, celecoxib is identified to possess inhibitory effect on Wnt, STAT3, RXR, Notch, and ERK/MAPK signaling pathways in gastric cancer cells. As previously reported, celecoxib inhibits Wnt and STAT3 signaling. In addition, for the first time, we have identified the inhibition of Notch, RXR and ERK/MAPK signaling upon celecoxib treatment in gastric cancer cell lines. Since MAPK plays very crucial oncogenic role, downregulation of this pathway along with the above mentioned other signaling processes makes gastric cancer cell lines more sensitive to celecoxib. The observation of Notch signaling activation upon nimesulide treatment in gastric cancer cell lines must be carefully studied because of its lineage/context dependent tumor suppressor/oncogenic functions [51,52]. Therefore, in the context of Notch signaling modulation, celecoxib could be better therapeutic candidate towards the development of targeted gastric cancer therapeutics. However, the IRF1 signaling inhibition capability observed with nimesulide is not found with celecoxib and this discloses the existence of common and unique cellular targets for nimesulide and celecoxib (Figure 6E). Though, nimesulide being a clinically restricted drug in many countries...
including India for its hepatoxoxicity [53], the recently developed nimesulide analogues were devoid of hepatotoxicity and exhibits promising in vitro and in vivo anti-cancer activity [54]. Hence, the derivatives of nimesulide would be the possible repositioning candidates for targeted gastric cancer therapy, specifically to the tumors with activated identified pathways. This needs to be further investigated. Investigation of the synergistic effect of nimesulide and celecoxib on doxorubicin sensitivity in gastric cancer cell lines identified that nimesulide and celecoxib are capable of enhancing doxorubicin sensitivity. This combinational effect also forecasts the possible utilization of combined nimesulide/celecoxib therapy with selective chemotherapeutic agents such as doxorubicin for gastric cancer. A drug capable of inhibiting multiple oncogenic signaling pathways would be more advantageous and desirable for cancer therapeutics, and both nimesulide and celecoxib possess that capability. However, the target selectivity and specificity slightly varies between nimesulide and celecoxib. Nimesulide and celecoxib were capable of inhibiting Wnt/Myc/E2F, STAT3 and RXR mediated transcription. Nimesulide in addition can inhibit IRF signaling and could activate the Notch signaling. Celecoxib on the other hand could inhibit ERK/MAPK and Notch signaling in gastric cancer cells (Figure 6f). In accordance with MAPK signal inhibition, despite the characteristic higher concentrations of NSAIDs, while the GI50 of nimesulide in AGS cells is 262 μM that of celecoxib being 36 μM (data not shown). However, the direct involvement of the cumulative and specific signaling targeting in determining the extent of cancer cell growth inhibition needs to be investigated. Thus the current study outlines the beneficial and possible adverse effect of nimesulide and celecoxib through cancer cellular signaling targets and this could be selectively utilized for targeting gastric cancers through genomics guided stratification. In conclusion, we established a cell based Wnt modulator screening system in gastric cancer cell line and identified nimesulide as inhibitor of activated Wnt signaling and various oncogenic signaling pathways. For the first time we report multiple cellular signaling targets of nimesulide and celecoxib and thus provides molecular basis of drug responsiveness. Our study also further reveals Wnt, STAT3, RXX and IRF1 signaling pathways as therapeutically vulnerable targets due to their prevalent activation in gastric cancers and combined targeting of these would elicit a promising therapeutic effect. The identified combinations of signaling inhibition might be the unidentified reason for the clinical and therapeutic effectiveness of various NSAIDs like celecoxib and sulindac. Despite the clinical effectiveness, the molecular targets were not systematically investigated previously. For the first time, a comprehensive panel of signaling driven transcription factor activity profiling has been employed in delineating the molecular targets of a drug. This approach will be certainly useful for the identification of the cellular targets of many drugs and drug candidates in future.  

Conflict of Interest  
The authors disclose no potential conflicts of interest.  

Acknowledgment  
This work was supported by Department of Atomic Energy (DAE), Govt. of India, through the research grant No.6/08/2008/R&D-II-230R to Dr. Ganesan Kumaresan, Madurai Kamaraj University. The instrumentation supports by UGC-CCEGS, DBT-PLS, UGC-NRCBS, DST-FIST, UGC-CAS and DST-PURSE facilities of School of Biological Sciences, Madurai Kamaraj University are acknowledged. UGC-Mentorship Scholarship to Mr.Jayaparakash Periasamy is acknowledged. The authors thank Dr. Devarajan Karunagaran for his help in providing access to the luminescence reader facility at Indian Institute of Technology Madras.  

References  


